Acta Med. 2012, 55: 111-115

https://doi.org/10.14712/18059694.2015.47

Bisphosphonate-Related Osteonecrosis of the Jaws. A Severe Side Effect of Bisphosphonate Therapy

Zuzana Janovská

Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Czech Republic: Department of Dentistry

Received April 21, 2012
Accepted September 10, 2012

References

1. Abu-Id MH, Warnke PH, Gottschalk J, et al. “Bis-phossy jaws” – high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg. 2008 Mar; 36(2): 95–103. <https://doi.org/10.1016/j.jcms.2007.06.008>
2. Alons K, Kuijpers SC, De Jong E, Van Merkesteyn JP. Treating low- and medium- potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Feb; 107(2): 1–7. <https://doi.org/10.1016/j.tripleo.2008.09.021>
3. Bagan JV, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 2006 Mar; 42(3): 327–9. <https://doi.org/10.1016/j.oraloncology.2005.08.001>
4. Bauer JS, Beck N, Kiefer J, Stockmann P, Wichmann M, Eitner S. Awareness and education of patients receiving bisphosphonates. J Craniomaxillofac Surg. 2012 Apr; 40(3): 277–82. <https://doi.org/10.1016/j.jcms.2011.04.011>
5. Bedogni A, Saia G, Bettini G, et al. Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. Oral Oncol. 2011 May; 47(5): 420–4. <https://doi.org/10.1016/j.oraloncology.2011.02.024>
6. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate- induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008 Sep; 44(9): 857–69. <https://doi.org/10.1016/j.oraloncology.2007.11.012>
7. Carmagnola D, Celestino S, Abati S. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Dec; 106(6): 10–5. <https://doi.org/10.1016/j.tripleo.2008.07.011>
8. Dannemann C, Grätz KW, Riener MO, Zwahlen RA. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone. 2007 Apr; 40(4): 828–34. <https://doi.org/10.1016/j.bone.2006.11.023>
9. Diel IJ, Fogelman I, Al-Nawas B, et al. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol. 2007 Dec; 64(3): 198–207. <https://doi.org/10.1016/j.critrevonc.2007.07.005>
10. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg. 2006 Jul; 35(7): 588–93. <https://doi.org/10.1016/j.ijom.2006.02.022>
11. Eckert AW , Maurer P, Meyer L, et al. Bisphosphonate-related jaw necrosis – severe complication in maxillofacial surgery. Cancer Treat Rev. 2007 Feb; 33(1): 58–63. <https://doi.org/10.1016/j.ctrv.2006.09.003>
12. Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Nov; 110(5): 593–6. <https://doi.org/10.1016/j.tripleo.2010.05.067>
13. Erkan M, Bilgi O, Mutluoğlu M, Uzun G. Bisphosphonate-related osteonecrosis of the jaw in cancer patients and hyperbaric oxygen therapy. JOP. 2009 Sep 4; 10(5): 579–80.
14. Fedele S, Porter SR, D’Aiuto F, et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med. 2010 Nov; 123(11): 1060–4. <https://doi.org/10.1016/j.amjmed.2010.04.033>
15. Fehm T, Beck V, Banys M, et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol. 2009 Mar; 112(3): 605–9. <https://doi.org/10.1016/j.ygyno.2008.11.029>
16. Ferlito S, Puzzo S, Palermo F, Verzì P. Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases. Br J Oral Maxillofac Surg. 2012 Jul; 50(5): 425–9. <https://doi.org/10.1016/j.bjoms.2011.08.004>
17. Green J, Clézardin P. The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol. 2010 Jun; 37 Suppl 1: S3–11. <https://doi.org/10.1053/j.seminoncol.2010.06.003>
18. Hauer L, Hrušák D, Hostička L, Andrle P, Jambura J, Pošta P. Osteonekróza čelistí v souvislosti s celkovou léčbou bisfosfonáty – Doporučení pro praxi. LKS. 2011; 21(5): 94–105.
19. Hoefert S, Eufinger H. Relevance of a Prolonged Preoperative Antibiotic Regime in the Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw. J Oral Maxillofac Surg. 2011 Feb; 69(2): 362–80. <https://doi.org/10.1016/j.joms.2010.06.200>
20. Katz J, Gong Y, Salmasinia D, et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2011 Jun; 40(6): 605–11. <https://doi.org/10.1016/j.ijom.2011.02.002>
21. Kos M, Kuebler JF, Luczak K, Engelke W. Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. J Craniomaxillofac Surg. 2010 Jun; 38(4): 255–9. <https://doi.org/10.1016/j.jcms.2009.06.005>
22. Lee CY, David T, Nishime M. Use of platelet-rich plasma in the management of oral bisphosphonate-associated osteonecrosis of the jaw: a report of 2 cases. J Oral Implantol, 2007, 33(6): 371–382. <https://doi.org/10.1563/1548-1336(2007)33[371:UOPPIT]2.0.CO;2>
23. Lin C-H, Liu C-S, Lai S-W. Long-term use oral bisphosphonate-related osteonecrosis of the jaw without dental extraction in elderly: A case report, J Clin GerontolGeriatr, 2011 Mar; 2(1): 30–32.
24. Lo JC, O’Ryan FS , Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators. J Oral Maxillofac Surg. 2010 Feb; 68(2): 243–53. <https://doi.org/10.1016/j.joms.2009.03.050>
25. Lobato JV, Maurício AC, Rodrigues JM, et al. Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate. J Plast Reconstr Aesthet Surg. 2008; 61(1): 99–106. <https://doi.org/10.1016/j.bjps.2006.06.016>
26. Machálka M, Adam Z, Bulik O, Kozumplíková M. Osteonekróza čelistí při léčbě bisfosfonáty. Čes. Stomat. 2006; 106(5): 136–139.
27. Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg. 2011 Mar; 40(3): 277–84. <https://doi.org/10.1016/j.ijom.2010.11.002>
28. Martins MA, Martins MD, Lascala CA, et al. Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: A preliminary study. Oral Oncol. 2012 Jan; 48(1): 79–84. <https://doi.org/10.1016/j.oraloncology.2011.08.010>
29. Mast G, Otto S, Mücke T, et al. Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw. J Craniomaxillofac Surg. 2011 Nov 25. [Epub ahead of print]. Http://dx.doi.org/10.1016/j .jcms.2011.10.012. <https://doi.org/10.1016/j.jcms.2011.10.012>
30. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(10): 1238–9. <https://doi.org/10.1016/S0278-2391(03)00720-1>
31. McLeod NMH, Brennan PA, Ruggiero SL. Bisphosphonate osteonecrosis of the jaw: A historical and contemporary review. The Surgeon. 2012 Feb; 10(1): 36–42. <https://doi.org/10.1016/j.surge.2011.09.002>
32. Moretti F, Pelliccioni GA, Montebugnoli L, Marchetti C. A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Dec; 112(6): 777–82. <https://doi.org/10.1016/j.tripleo.2011.07.004>
33. Narongroeknawin P, Danila MI, Humphreys LG Jr, Barasch A, Curtis JR. Bisphosphonate- associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dentist, 2010, 30(2): 77–82. <https://doi.org/10.1111/j.1754-4505.2009.00128.x> <PubMed>
34. Nicolatou-Galitis O, Papadopoulou E, Sarri T, et al. Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Aug; 112(2): 195–202. <https://doi.org/10.1016/j.tripleo.2011.02.037>
35. O’Ryan FS, Khoury S, Liao W, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009 Jul; 67(7): 1363–72. <https://doi.org/10.1016/j.joms.2009.03.005>
36. Otto S, Schreyer C, Hafner S, et al. Bisphosphonate-related osteonecrosis of the jaws – Characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg. 2012 Jun; 40(4): 303–9. <https://doi.org/10.1016/j.jcms.2011.05.003>
37. Pavlicová A, Vavřičková L, Slezák R, Mottl R. Vlastní zkušenosti s léčbou bisfosfonáty indukovanou osteonekrózou čelistních kostí. LKS. 2010; 20(5): 104–108.
38. Peřina V, Pokorný P, Machálka M, Liberda O. Osteonekróza čelisti při léčbě bisfosfonáty. LKS. 2008; 18(5): 129–156.
39. Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I–II study. Oral Oncol. 2011 Mar; 47(3): 185–90. <https://doi.org/10.1016/j.oraloncology.2011.01.002>
40. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009 Jan; 20(1): 137–45. <https://doi.org/10.1093/annonc/mdn526>
41. Schubert M, Klatte I, Linek W, et al. The Saxon Bisphosphonate Register – T herapy and prevention of bisphosphonate-related osteonecrosis of the jaws. Oral Oncol. 2012 Apr; 48(4): 349–54. <https://doi.org/10.1016/j.oraloncology.2011.11.004>
42. Tubiana-Hulin M, Spielmann M, Roux C, et al. Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Crit Rev Oncol Hematol. 2009 Jul; 71(1): 12–21. <https://doi.org/10.1016/j.critrevonc.2008.10.009>
43. Vescovi P, Campisi G, Fusco V, et al. Surgery-triggered and non surgery-triggered Bisphosphonate-related osteonecrosis of the jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol. 2011 Mar; 47(3): 191–4. <https://doi.org/10.1016/j.oraloncology.2010.11.007>
44. Vieillard MH, Maes JM, Penel G, et al. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine. 2008 Jan; 75(1): 34–40. <https://doi.org/10.1016/j.jbspin.2007.05.003>
45. Wilde F, Heufelder M, Winter K, et al. The role of surgical therapy in the management of intravenous bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Feb; 111(2): 153–163. <https://doi.org/10.1016/j.tripleo.2010.04.015>
46. Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int. J. Oral Maxillofac. Surg. 2010; 39(3): 251–255. <https://doi.org/10.1016/j.ijom.2009.11.014>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Archive